亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

医学 硼替佐米 耐受性 威尼斯人 安慰剂 多发性骨髓瘤 临床终点 地塞米松 内科学 人口 临床试验 肿瘤科 中性粒细胞减少症 临床研究阶段 蛋白酶体抑制剂 不利影响 化疗 白血病 替代医学 病理 慢性淋巴细胞白血病 环境卫生
作者
Shaji Kumar,Simon J. Harrison,Michèle Cavo,Javier de la Rubia,Rakesh Popat,Cristina Gasparetto,Vânia Hungria,Hans Salwender,Kenshi Suzuki,Inho Kim,Elizabeth A. Punnoose,Wan-Jen Hong,Kevin J. Freise,Xiaoqing Yang,Anjla Sood,Muhammad Jalaluddin,Jeremy A. Ross,Jeffery C. Ward,Paulo Maciag,Philippe Moreau
出处
期刊:Lancet Oncology [Elsevier]
卷期号:21 (12): 1630-1642 被引量:295
标识
DOI:10.1016/s1470-2045(20)30525-8
摘要

Summary

Background

Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has shown encouraging clinical efficacy with acceptable safety and tolerability in a phase 1 trial. The aim of this study was to evaluate venetoclax plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Methods

In this randomised, double-blind, multicentre, phase 3 trial, patients aged 18 years or older with relapsed or refractory multiple myeloma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received one to three previous therapies were enrolled from 90 hospitals in 16 countries. Eligible patients were randomly assigned (2:1) centrally using an interactive response technology system and a block size of three to receive venetoclax (800 mg per day orally) or placebo with bortezomib (1·3 mg/m2 subcutaneously or intravenously and dexamethasone (20 mg orally). Treatment was given in 21-day cycles for the first eight cycles and 35-day cycles from the ninth cycle until disease progression, unacceptable toxicity, or patient withdrawal. Randomisation was stratified by previous exposure to a proteasome inhibitor and the number of previous therapies. Sponsors, investigators, study site personnel, and patients were masked to the treatment allocation throughout the study. The primary endpoint was independent review committee-assessed progression-free survival in the intention-to-treat population. Safety analyses were done in patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT02755597.

Findings

Between July 19, 2016, and Oct 31, 2017, 291 patients were randomly assigned to receive venetoclax (n=194) or placebo (n=97). With a median follow-up of 18·7 months (IQR 16·6–21·0), median progression-free survival according to independent review committee was 22·4 months (95% CI 15·3–not estimable) with venetoclax versus 11·5 months (9·6–15·0) with placebo (hazard ratio [HR] 0·63 [95% CI 0·44–0·90]; p=0·010). The most common grade 3 or worse treatment-emergent adverse events were neutropenia (35 [18%] of 193 patients in the venetoclax group vs seven [7%] of 96 patients in the placebo group), pneumonia (30 [16%] vs nine [9%]), thrombocytopenia (28 [15%] vs 29 [30%]), anaemia (28 [15%] vs 14 [15%]), and diarrhoea (28 [15%] vs 11 [11%]). Serious treatment-emergent adverse events occurred in 93 (48%) patients in the venetoclax group and 48 (50%) patients in the placebo group, with eight (4%) treatment-emergent fatal infections reported in the venetoclax group and none reported in the placebo group. Three deaths in the venetoclax group (two from pneumonia and one from septic shock) were considered treatment-related; no deaths in the placebo group were treatment-related.

Interpretation

The primary endpoint was met with a significant improvement in independent review committee-assessed progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone. However, increased mortality was seen in the venetoclax group, mostly because of an increased rate of infections, highlighting the importance of appropriate selection of patients for this treatment option.

Funding

AbbVie and Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
xyw发布了新的文献求助10
7秒前
上官若男应助chh采纳,获得10
9秒前
11秒前
11秒前
14秒前
头大四年发布了新的文献求助10
16秒前
17秒前
sissiarno应助科研通管家采纳,获得30
20秒前
20秒前
sissiarno应助科研通管家采纳,获得30
20秒前
慕青应助高兴的无颜采纳,获得10
20秒前
21秒前
24秒前
饭团不吃鱼完成签到,获得积分10
24秒前
24秒前
慕青应助走走采纳,获得10
26秒前
chh发布了新的文献求助10
26秒前
西早发布了新的文献求助10
27秒前
狼牧羊城完成签到,获得积分10
38秒前
高兴的无颜完成签到,获得积分10
41秒前
pegasus0802完成签到,获得积分10
43秒前
飘着的鬼完成签到,获得积分10
44秒前
48秒前
50秒前
54秒前
走走发布了新的文献求助10
54秒前
1分钟前
GT完成签到,获得积分10
1分钟前
体育爱好者完成签到,获得积分10
1分钟前
旺旺小小贝完成签到,获得积分10
1分钟前
牟白容发布了新的文献求助30
1分钟前
牟白容完成签到,获得积分10
1分钟前
1分钟前
落后的忆文关注了科研通微信公众号
1分钟前
1分钟前
1分钟前
hillson发布了新的文献求助10
1分钟前
头大四年发布了新的文献求助10
1分钟前
hank完成签到,获得积分10
1分钟前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Diamonds: Properties, Synthesis and Applications 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099715
求助须知:如何正确求助?哪些是违规求助? 2751149
关于积分的说明 7611895
捐赠科研通 2402905
什么是DOI,文献DOI怎么找? 1275047
科研通“疑难数据库(出版商)”最低求助积分说明 616226
版权声明 599033